InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.575 0.566 (6,288.89%)+
Announcement
Release
21 Nov 2025 9:20AM
Price at Release
$0.009
Full Release
download
Summary
Alterity Therapeutics Limited announced significant changes to its Board of Directors as part of its strategic alignment for the next phase of growth. Mr. Geoffrey Kempler, a founding shareholder and former CEO, retired from his role as Non-Executive Chairman, and Mr. Brian Meltzer also retired as Non-Executive Director, marking a transition to a new leadership generation. Dr. David Stamler, previously the Chief Executive Officer, was appointed as Managing Director and CEO, and Mr. Julian Barbaczy joined as the Non-Executive Chair, bringing extensive finance and investment expertise. These board changes aim to support Alterity's progress towards Phase 3 clinical development, particularly for its lead asset ATH434 in treating Multiple System Atrophy, a neurodegenerative disorder.
Key Points
  • Mr. Geoffrey Kempler retired as Non-Executive Chairman.
  • Mr. Brian Meltzer retired as Non-Executive Director.
  • Dr. David Stamler appointed as Managing Director and CEO.
  • Mr. Julian Barbaczy joined as Non-Executive Chair.
  • Changes support Alterity's Phase 3 clinical development for ATH434.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.